CN Bio adds Human 24 to PhysioMimix to aid drug toxicity testing
CN Bio has launched its PhysioMimix DILI (drug-induced liver injury) assay kit: Human 24.
Based on Cambridge Science Park, CN Bio develops organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows.
Built on CN Bio’s human-derived and highly characterised liver microphysiological system (MPS), the DILI assay kit provides robust, human-relevant insights into crucial drug safety parameters, to support more informed clinical progression of drug candidates, enhanced clinical preparedness, and helps de-risk drug development workflows by ensuring only the most promising therapeutic candidates are selected.
Dr Ovidiu Novac, senior scientist and project manager (DILI assay kit), CN Bio, said: “Toxicology testing is perhaps the most essential part of developing a new drug.
“With Human 24, PhysioMimix users can now more easily replicate our industry-leading DILI assay in their own lab, providing deeper mechanistic insights into drug-induced hepatoxicity and enabling more confident progression of drug candidates into the clinic.”